SGLT2 inhibitors are a class of medications that not only lower blood sugar in people with type 2 diabetes but also provide additional benefits like weight loss, blood pressure reduction, and kidney and heart protection. Yet, high costs often put these powerful drugs out of reach for many who need them.

Approved in 2023, Brenzavvy is a relatively new SGLT2 inhibitor for type 2 diabetes. What sets it apart from other medications in its class is the price: $50 per month. However, Brenzavvy was only available through online pharmacies like Cost Plus Drugs – until now.

Brenzavvy manufacturer TheracosBio is now offering the medication at Publix pharmacies, which have over 1,300 locations across the U.S., for $50 month. This amount is notably less than other SGLT2 inhibitors, many of which are sold at a retail price of hundreds of dollars per month.

Considering that recent legislation is putting millions of people at risk of losing health insurance, access to affordable blood sugar-lowering medication is more important than ever – especially for those paying out of pocket.